5-((2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride

Catalog No. :
ACCNAN072
CAS No. :
2863635-01-0
Molecular Formula :
C21H29ClN4O7
Molecular Weight :
484.94

IUPAC Name:5-((2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride

5-((2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-((2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride
IUPAC Name5-((2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride
Molecular FormulaC21H29ClN4O7
Molecular Weight484.94
SMILESO=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC(NCCOCCOCCOCCN)=C3)=O.[H]Cl
InChI KeyVCNANDVZHBZWEE-UHFFFAOYSA-N
SynonymThalidomide-5-NH-PEG3-NH2 hydrochloride;1H-Isoindole-1,3(2H)-dione, 5-[[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethyl]amino]-2-(2,6-dioxo-3-piperidinyl)-, hydrochloride (1:1);Thalidomide 5'-amine-PEG3-amine
CAS No.2863635-01-0

Safety Data

Pictogram
Health hazard
Signal Word
Gefahr
Hazard Statement(s)
H360
Precautionary Statement(s)
P201-P202-P280-P308+P313-P405-P501

Synthetic Route by SureRoute

1. ACCNAN072 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACCNAN072 route product structure diagram
    ACCNAN0722863635-01-0
Inquiry

2. ACCNAN072 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACCNAN072 route product structure diagram
    ACCNAN0722863635-01-0
Inquiry

Comments (0)